ADAM17 and acute myeloid leukemia: The CD16 × CD33 BiKE activated NK cells against de novo and refractory AML cells, and when combined with an ADAM17 inhibitor was able to overcome the MHC-1 inhibitory signals, when MHC-1 was expressed in AML cells [33].